AI assistant
Sending…
Tharimmune, Inc. — Director's Dealing 2022
May 25, 2022
34824_dirs_2022-05-25_42ab990c-c527-424d-a1b6-1defee9c7ce7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-05-25
Reporting Person: MILBY RANDY (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-25 | Common Stock | P | 200 | $0.77 | Acquired | 2936739 | Direct |
| 2022-05-25 | Common Stock | P | 800 | $0.79 | Acquired | 2937539 | Direct |
More from Tharimmune, Inc.
Interim / Quarterly Report
2026
May 13
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Feb 18
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11